Annovis Bio (NYSE: ANVS) has promoted Cheng Fang, Ph.D., to chief scientific officer, the company announced. Fang, who joined Annovis in 2021 and most recently served as senior vice president of research and development, will oversee scientific strategy and research operations across the company's Alzheimer's disease and Parkinson's disease programs. His responsibilities include translational science, clinical development, biomarker strategy and regulatory interactions.
Fang's promotion comes at a critical time as Annovis advances its lead drug candidate, buntanetap, toward top-line data from its pivotal Phase 3 Alzheimer's disease study and a subsequent New Drug Application submission. The company stated that Fang has been instrumental in advancing its clinical development efforts and will lead scientific strategy through upcoming milestones. According to the press release, Fang's role will be key in navigating the regulatory and clinical phases ahead.
Annovis Bio is a Phase 3 clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. Its lead candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy designed to inhibit the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism. By addressing underlying causes of neurodegeneration, the company aims to halt disease progression and improve cognitive and motor functions in patients. More information is available at www.annovisbio.com.
This leadership change signals Annovis's preparation for a pivotal phase in its development pipeline. The advancement of buntanetap through Phase 3 trials represents a potential breakthrough in Alzheimer's treatment, as current therapies only manage symptoms. Fang's expertise in translational science and biomarker strategy will be crucial for interpreting clinical data and guiding regulatory interactions. The company's focus on multiple neurotoxic proteins distinguishes buntanetap from other candidates, potentially offering a more comprehensive approach to neurodegeneration.
Investors and the scientific community will be watching closely as Annovis approaches the release of top-line data. Positive results could position buntanetap as a disease-modifying therapy for Alzheimer's, addressing a significant unmet medical need. The promotion of Fang underscores the company's commitment to advancing its pipeline and preparing for commercialization. For continuous updates, the company's newsroom is available at https://ibn.fm/ANVS.
